

Cover Story
ClinicalRegulatory NewsTrials & Tribulations
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Vermont researchers discover transmissible cancer in catfish—first ever in a freshwater animal
- The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Patricio Polanco named chief of surgical oncology and surgeon-in-chief at Atrium Health Levine Cancer

















